PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34672825-7	2021	For HER2+ patients, use of CIT treatment downtrended with progression of pathological stage, from 70.1% (stage I) to 58.1% (stage III).	cit	27-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8